Cancer drug demand drives higher sales for AstraZeneca - Revenues from oncology products made up 43% of the company’s total ...

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver $80 billion ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the United States. Revenue climbed 12 percent to ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

AstraZeneca is raising its defenses against Johnson & Johnson in a fierce competition in EGFR-mutated non-small cell lung cancer. | Following an FDA approval last year based on a tumor progression ...

AstraZeneca (LSE: AZN) posted a robust second-quarter 2025 performance, lifted by record growth in its US business and solid ...

AstraZeneca share price held steady this week after the company published strong financial results on Tuesday.

AstraZeneca has a strong portfolio of cancer drugs, which is the major revenue generating segment for the company. Sales from the oncology segment was $5.3 billion in the first half of 2020.

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...